p53 Mar 22, 2022 Affini-T Therapeutics Raises $175M in Financing Round Nov 19, 2021 Rain Therapeutics Begins Basket Trial Evaluating Milademetan for MDM2-Amplified Solid Tumors Nov 9, 2021 Athenex Garners Rights to NCI-Discovered TCRs for Cell Therapies Development in Solid Tumors Jul 2, 2021 Aileron Therapeutics Begins Phase Ib Trial of Chemoprotective Drug in p53-Mutated NSCLC Apr 22, 2021 Illumina, Kartos Therapeutics Partner to Develop TP53 Companion Diagnostic Apr 7, 2021 Roche Elecsys Anti-p53 Test for Cancer Diagnosis Earns CE Mark Mar 10, 2021 Impact Therapeutics Begins US Study of Synthetic Lethality WEE1 Inhibitor IMP7068 Mar 8, 2021 Immunotherapy With Bispecific Antibodies Targets T Cells to Cancer Cells' Mutant Peptides Premium Dec 29, 2020 Aprea's Eprenetapopt Fails to Meet Primary Endpoint in Phase III Trial of TP53-Mutant MDS Nov 25, 2020 PMV Pharma Begins Trial of Investigational Drug in p53-Mutated Cancers Oct 7, 2020 Aprea Therapeutics to Begin Phase I Trial for APR-548 in Myelodysplastic Syndromes Aug 14, 2020 MDS Patients Fare Worse With Two Mutated Copies of TP53 Than One, Research Shows Premium Jul 16, 2020 Aprea Therapeutics Expanding Eprenetapopt Trial in TP53-Mutant Acute Myeloid Leukemia Jul 13, 2020 Discovery of Inherited Mutation Sheds Light on Increased Cancer Risk in Brazilians Premium Jun 29, 2020 Aileron Therapeutics Enrolling TP53-Mutated Lung Cancer Patients in Phase IB/II Study Jun 19, 2020 Aprea's Drug for TP53-Mutant Cancers Moves Into Registrational Trials for Myelodysplastic Syndromes Premium Sep 10, 2019 Repare Therapeutics Using CRISPR to Develop Cancer Treatments for Synthetic Lethal Targets Premium Breaking News FDA Approves Taiho Oncology's Lytgobi for FGFR2-Rearranged Bile Duct Cancer Gladstone Institute Joins With Parker Institute on New Center to Study CRISPR-Based Cell Therapies Meliora Therapeutics Raises $11M in Seed Financing In Brief This Week:Â Verismo Therapeutics, Fore Biotherapeutics, Merck, Caris Life Sciences Tumor-Only Sequencing Found to Overestimate Mutational Burden in Non-European Patients Atara Biotherapeutics to Net $30M From Pierre Fabre for European Tab-Cel Approval
